Compare · FMS vs PGNY
FMS vs PGNY
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 6.6x PGNY ($1.98B).
- Over the past year, FMS is down 7.8% and PGNY is up 14.2% - PGNY leads by 22.0 points.
- FMS has been more active in the news (7 items in the past 4 weeks vs 6 for PGNY).
- PGNY has more recent analyst coverage (25 ratings vs 23 for FMS).
- Company
- Fresenius Medical Care AG
- Progyny Inc.
- Price
- -
- -
- Market cap
- $13.13B
- $1.98B
- 1M return
- -5.62%
- -18.21%
- 1Y return
- -7.83%
- +14.16%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 6
- Recent ratings
- 23
- 25
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target
Latest PGNY
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Progyny, Inc. Announces Second Quarter 2026 Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- Progyny downgraded by Barclays with a new price target
- Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
- Chief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation